APA 6th Edition LUCIC VRDOLJAK, A., BRADAMANTE, V., RADIC, B., PERAICA, M., FUCHS, R. i REINER, Z. (2005). Butyrylcholinesterase activity and plasma lipids in dexamethasone treated rats. Acta Pharmaceutica, 55 (2), 177-185. Preuzeto s https://hrcak.srce.hr/16755
MLA 8th Edition LUCIC VRDOLJAK, ANA, et al. "Butyrylcholinesterase activity and plasma lipids in dexamethasone treated rats." Acta Pharmaceutica, vol. 55, br. 2, 2005, str. 177-185. https://hrcak.srce.hr/16755. Citirano 26.01.2020.
Chicago 17th Edition LUCIC VRDOLJAK, ANA, VLASTA BRADAMANTE, BOZICA RADIC, MAJA PERAICA, RADOVAN FUCHS i ZELJKO REINER. "Butyrylcholinesterase activity and plasma lipids in dexamethasone treated rats." Acta Pharmaceutica 55, br. 2 (2005): 177-185. https://hrcak.srce.hr/16755
Harvard LUCIC VRDOLJAK, A., et al. (2005). 'Butyrylcholinesterase activity and plasma lipids in dexamethasone treated rats', Acta Pharmaceutica, 55(2), str. 177-185. Preuzeto s: https://hrcak.srce.hr/16755 (Datum pristupa: 26.01.2020.)
Vancouver LUCIC VRDOLJAK A, BRADAMANTE V, RADIC B, PERAICA M, FUCHS R, REINER Z. Butyrylcholinesterase activity and plasma lipids in dexamethasone treated rats. Acta Pharm. [Internet]. 2005 [pristupljeno 26.01.2020.];55(2):177-185. Dostupno na: https://hrcak.srce.hr/16755
IEEE A. LUCIC VRDOLJAK, V. BRADAMANTE, B. RADIC, M. PERAICA, R. FUCHS i Z. REINER, "Butyrylcholinesterase activity and plasma lipids in dexamethasone treated rats", Acta Pharmaceutica, vol.55, br. 2, str. 177-185, 2005. [Online]. Dostupno na: https://hrcak.srce.hr/16755. [Citirano: 26.01.2020.]
Sažetak The paper describes the effect of glucocorticoide dexamethasone (DM) given intraperitoneally on the catalytic activity of butyrylcholinesterase (BuChE) measured in plasma, liver and white adipose tissue of rats of both sexes. Effects of DM on the concentration of plasma lipids and lipoproteins were also tested. Rats were given multiple (2 and 4) pharmacological doses (0.4 and 3.0 mg kg-1 body mass) of DM. All animals were sacrificed 48 h after the last dose. Administration of DM significantly decreased the catalytic activity of BuChE in plasma and liver of all treated groups regardless of sex. BuChE catalytic activity in white adipose tissue differed depending on the dose and frequency of administration. In contrast to liver where both doses caused significant BuChE inhibition, the lower DM dose did not inhibit BuChE activity in adipose tissue, and the inhibition achieved by the higher dose was not as strong as in liver. This result corroborates an earlier hypothesis that BuChE is also synthesized in the adipose tissue. DM significantly increased plasma concentrations of triglycerides, total cholesterol and high-density lipoprotein (HDL) cholesterol and decreased the low-density lipoprotein (LDL) cholesterol concentration. Neither positive correlation between BuChE and triglycerides nor negative correlation between BuChE and HDL was found. Changes in lipid profile during DM treatment were not sex- and time-dependent.